The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer.
 
Jacek Grabowski
Honoraria - Abbvie; AstraZeneca/Merck; Eisai; Esteve; GlaxoSmithKline; MSD
Consulting or Advisory Role - Abbvie; AstraZeneca/Merck; GlaxoSmithKline; MSD
Speakers' Bureau - Abbvie; AstraZeneca/Merck; Eisai; Esteve; GlaxoSmithKline; MSD
Research Funding - Abbvie (Inst); AstraZeneca/Merck (Inst); Esteve (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/Merck; GlaxoSmithKline
 
Elena Ioana Braicu
Honoraria - Abbvie; AstraZeneca; North Eastern German Society for Gynecologic Oncology
Consulting or Advisory Role - Abbvie; GlaxoSmithKline; Immunogen; IQvia (Inst); MSD; Myriad Genetics; Pharma And; Torl Biotherapeutics; Tubulis GmbH
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Iqvia (Inst); MSD (Inst); Roche Molecular Diagnostics (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - North Eastern German Society of Gynecologic Oncology (NOGGO eV)
 
Philipp Harter
Honoraria - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Exscientia; GlaxoSmithKline; Karyopharm Therapeutics; Lilly; Mersana; MSD Oncology; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Clovis Oncology; Corcept Therapeutics; Eisai; Exscientia; GlaxoSmithKline; Immunogen; Merck; Mersana; Miltenyi Biomedicine; MSD Oncology; Novartis; Roche; Tesaro; Zymeworks
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Immunogen (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Dario Zocholl
Travel, Accommodations, Expenses - Merck KGaA
 
Lea-Jean Pietzke
No Relationships to Disclose
 
Florian Heitz
Honoraria - AstraZeneca; Immunogen; Roche; Seagen; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novocure; PharmaMar; Roche; Zai Lab
Research Funding - Amedes (Inst); AstraZeneca (Inst)
 
Tjadina Arndt
No Relationships to Disclose
 
Julia Welz
No Relationships to Disclose
 
Jalid Sehouli
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Clovis Oncology; Corcept Therapeutics; Daiichi; Eisai; Esteve Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Hexal; Incyte; Jenapharm; Johnson & Johnson; Kyowa Kirin International; Medtronic Covidien; MSD Oncology; Myriad Pharmaceuticals; Novartis; Oncoinvent; Pfizer; PharmaMar; Phytolife Nutrition; Roche; Vifor Pharma
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer/Vital; Bristol Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Eisai; GlaxoSmithKline; Immunogen; Ingress Health; Intuitive Surgical; Johnson & Johnson; Karyopharm Therapeutics; Lilly; Merck; MSD Oncology; Mundipharma; Novocure; Oncoinvent; Pfizer; PharmaMar; Roche; Sanofi Aventis GmbH; Seagen; Sobi; Tubulis GmbH
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); IQvia (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); MSD Oncology (Inst); Mural (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG